The Daily Buyout

The archive

Every deal we've covered

996 deals tracked since Aug 26, 2026, worth $506B in announced deal value. Every link is free to read.

20 deals · $23.9B announced on this page
~$1.4BreportedTake-privateTechnologyOct 12, 2026

Persistent locks up 94% of Nagarro, plans squeeze-out

India's Persistent Systems has secured about 94.04% of German digital engineering firm Nagarro after its voluntary takeover offer closed. Tendered shares totaled about 71.94%, on top of a 22.10% stake bought from Lantano Beteiligungen. That is well above the 50%-plus-one-share threshold. Having passed 90%, Persistent plans to squeeze out remaining minority holders and take Nagarro private.

$5.8BTake-privateHealthcare & Life SciencesOct 7, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

$5.8BTake-privateHealthcare & Life SciencesOct 6, 2026

CD&R and McKesson to take Option Care Health private at $5.8B value

CD&R and McKesson signed a definitive agreement to acquire Option Care Health, an independent provider of home and alternate site infusion services, for $32.05 per share in cash, reflecting a total enterprise value of about $5.8 billion. The Nasdaq-listed company will be taken private through the joint private equity and strategic partnership.

~$375MreportedTake-privateHealthcare & Life SciencesCompletedOct 6, 2026

Altaris completes take-private of Simulations Plus

Simulations Plus, the Nasdaq-listed developer of model-informed and AI-accelerated drug development software, announced the completion of its acquisition by affiliates of healthcare-focused investment firm Altaris. The transaction was originally announced on June 16, 2026, and shares of the company were converted at the effective time of the merger.

~$3.7BreportedTake-privateMaterials & ChemicalsCompletedSep 30, 2026

Apollo completes take-private of Nippon Sheet Glass

Apollo-managed funds closed their acquisition of Nippon Sheet Glass, the global architectural, automotive and solar glass maker, and launched a new management structure for the company. Apollo says the deal, done with key financial institutions, will strengthen NSG's balance sheet and fund investment in people and technology. NSG's president called the closing the start of a new chapter for the century-old group.

$114MTake-privateTechnologySep 30, 2026

Transom Capital to take SoundThinking private at up to $11 a share

Public safety technology company SoundThinking agreed to be acquired by Transom Capital Group via a tender offer of $8.00 per share in cash plus a contingent value right worth up to $3.00 more, for up to $11.00 per share. The upfront price is a 46% premium to the prior close and implies a $114 million enterprise value, rising to about $159 million if the CVR pays out fully. Holders of roughly 33% of shares have agreed to tender.

$5.7BTake-privateHealthcare & Life SciencesSep 30, 2026

KKR's $5.7B Integer buyout clears antitrust review early

Integer Holdings said it received early termination of the Hart-Scott-Rodino waiting period for its pending acquisition by an affiliate of KKR-managed funds. The August 2 merger agreement values the medical device CDMO at $127 per share in cash, or roughly $5.7 billion in enterprise value. Shareholders vote at a special meeting on October 21, and the parties still expect to close by the end of 2026 pending other regulatory approvals.

$664MTake-privateHealthcare & Life SciencesSep 29, 2026

Webster Equity to take Lifecore Biomedical private in deal worth up to $664M

Lifecore Biomedical agreed to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of performance milestones. Shareholders receive $6.28 per share in cash at closing plus one non-tradable contingent right. Management framed the deal as funding the CDMO's next growth phase, with multiple customer programs potentially commercializing by the end of 2028.